Spectral AI Stock Price, News & Analysis
Company Description
Spectral AI, Inc. (warrants trading on Nasdaq under the symbol MDAIW) is a Dallas-based predictive artificial intelligence company in the healthcare sector. According to the company’s disclosures, it focuses on medical diagnosticswound care, with initial applications for patients with burns. Its work sits at the intersection of medical devices, imaging technology, and AI-driven clinical decision support.
The company is developing its proprietary DeepView System, described as a non-invasive, predictive medical device and software platform. Based on the available information, DeepView combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of burn wounds. The system is being designed to provide clinicians with an objective and immediate assessment of whether a burn wound is likely to heal, supporting more informed treatment decisions in burn care settings.
Business focus and technology
Spectral AI states that it is focused on using AI for predictive medical diagnostics in wound care. The DeepView System is being developed to offer clinicians an objective assessment of a burn wound’s healing potential prior to treatment or other medical intervention. Company materials describe the output as algorithm-driven and intended to provide fast treatment insight that may improve patient outcomes and reduce healthcare costs.
In regulatory communications, Spectral AI notes that the DeepView System received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2018. The company has also reported the submission of a De Novo 510(k) marketing clearance application to the FDA for DeepView, intended for use in burn care settings, including burn centers and emergency departments. The De Novo pathway is being pursued because the technology does not have a predicate device currently available in the U.S. market, reflecting its novel character as described by the company.
DeepView System and wound care applications
According to Spectral AI, the DeepView System is designed to support clinicians by providing a non-healing prediction on the same day of injury and up to seven days post injury. This prediction is based on multispectral imaging data analyzed by proprietary AI algorithms. The company describes this as enabling earlier and more informed treatment decisions in burn care.
In multiple company press releases, Spectral AI emphasizes that DeepView is being developed as a predictive device to offer objective and immediate assessments of burn wounds. The system is described as a tool that can assist clinical decision-making, with the stated goal of exceeding the current standard of care in the future by improving the speed and accuracy of wound assessment.
Presence in clinical and professional forums
Spectral AI reports that its DeepView technology has been featured in presentations and posters at several burn-focused medical conferences. These include the British Burn Association conference, the European Burns Association congress, and regional U.S. burn conferences such as the Southern Region Burn Conference and the Northeast Region Burn Conference. Presentations referenced by the company have discussed topics such as multispectral imaging and burn healing potential, AI-enhanced imaging for burn assessment, early clinical experiences with DeepView in burn centers, and patient experience with AI-based imaging in burns consultations.
Comments cited in company news releases from clinicians in the United Kingdom, the United States, and Australia describe early experiences with DeepView in real-world burn care environments. These comments, as reported by Spectral AI, highlight interest in AI-enhanced imaging for burn depth assessment, healing prediction, and potential improvements in the consistency of clinical decision-making.
Regulatory and development context
From its public statements, Spectral AI characterizes itself as an emerging growth company and notes that it is devoting substantial efforts to the research and development of the DeepView System. The company’s filings and press releases indicate that DeepView has been supported by contracts with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). These contracts have funded aspects of the technology’s advanced development, including clinical trials and studies related to burn wound assessment.
Financial updates from Spectral AI describe revenue categorized as research and development revenue, associated with its BARDA Project BioShield contract and related reimbursed study costs. The company also reports efforts to manage operating expenses and obtain growth capital, including equity offerings and debt financing, to support continued development and preparation for potential commercialization of DeepView.
Listing and securities
Spectral AI’s redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $2.75 per share, trade on The Nasdaq Stock Market LLC under the symbol MDAIW. In its SEC filings, the company identifies itself as an emerging growth company and lists these warrants as a registered class of securities.
The company’s common stock trades under a separate Nasdaq symbol, while MDAIW specifically refers to the warrants. Investors reviewing MDAIW are therefore looking at a derivative security linked to Spectral AI’s common shares.
Recognition and positioning
In a company news release, Spectral AI reports that it was named on TIME’s list of World’s Top HealthTech companies 2025. The company also consistently uses the phrase “Seeing the Unknown” in connection with DeepView, reflecting its stated aim of revealing clinically relevant information about wound healing potential that may not be visible to the naked eye.
Across its public communications, Spectral AI presents itself as working to change the management of wound care by providing AI-driven tools that deliver objective imaging-based assessments. Its focus remains on burn indications as an initial application area, with references to broader wound care markets in its descriptive materials.
Geographic base and sector classification
Spectral AI identifies itself as Dallas-based and operates in the healthcare sector, with an industry focus on medical diagnostics and wound care. The DeepView System is characterized as a medical device platform that integrates imaging hardware and AI software, aligning the company with the medical devices and health technology segments within healthcare.
FAQs about Spectral AI, Inc. (MDAIW)
- What does Spectral AI, Inc. do?
Spectral AI, Inc. is a predictive AI company focused on medical diagnostics for wound care. It is developing the DeepView System, a non-invasive device and software platform intended to assess the healing potential of burn wounds using multispectral imaging and AI algorithms. - What is the DeepView System?
According to the company, the DeepView System is a predictive medical device and associated software platform that combines multispectral imaging with a proprietary AI algorithm. It is being developed to provide clinicians with an objective and immediate assessment of burn wound healing potential, including a non-healing prediction from the day of injury up to seven days after injury. - Which medical area does Spectral AI focus on?
Spectral AI focuses on wound care, with initial applications involving patients with burns. Its DeepView technology is intended for use in burn care settings such as burn centers and emergency departments, based on the company’s descriptions. - What is special about DeepView’s regulatory status?
Company disclosures state that the DeepView System received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2018. Spectral AI has also reported submitting a De Novo 510(k) marketing clearance application to the FDA for DeepView, reflecting the novel nature of the technology and the absence of a predicate device in the U.S. market. - How does Spectral AI describe the benefits of DeepView?
In its press releases, Spectral AI states that DeepView is expected to provide fast, algorithm-driven treatment insight that may improve patient outcomes and reduce healthcare costs. The system is described as offering objective, immediate assessments that can assist clinicians in making more accurate and timely decisions about burn wound treatment. - Where is Spectral AI based?
Spectral AI describes itself as a Dallas-based company. Its SEC filings list a Dallas, Texas location as the address for the registrant. - On which exchange do Spectral AI warrants trade, and what is MDAIW?
Spectral AI’s redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $2.75 per share, are listed on The Nasdaq Stock Market LLC under the symbol MDAIW. These warrants are a separate security from the company’s common stock. - How is the development of DeepView funded?
Spectral AI reports that development of DeepView has been supported by federal funds through contracts with BARDA, part of the U.S. Department of Health and Human Services. The company also records research and development revenue related to this contract and has raised additional capital through equity and debt financings. - In what professional settings has DeepView been discussed?
Company news releases state that DeepView has been featured in presentations and posters at conferences such as the British Burn Association conference, the European Burns Association congress, and U.S. regional burn conferences. These sessions have covered topics like AI-enhanced multispectral imaging, burn healing potential, and early clinical experiences with DeepView. - What does Spectral AI mean by “Seeing the Unknown”?
“Seeing the Unknown” is a phrase used by Spectral AI in its descriptions of the DeepView System. It reflects the company’s goal of using AI and multispectral imaging to reveal information about wound healing potential that is not visible to the naked eye, supporting more informed clinical decisions in burn care.